285 related articles for article (PubMed ID: 24627175)
1. Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma.
Thomson NC
Evid Based Med; 2014 Aug; 19(4):135. PubMed ID: 24627175
[No Abstract] [Full Text] [Related]
2. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
Di Stefano F; Cinti B; Antonicelli L
Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
4. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
Asai N; Ohkuni Y; Komatsu A; Matsunuma R; Nakashima K; Kaneko N
J Bras Pneumol; 2011; 37(4):567-70. PubMed ID: 21881749
[No Abstract] [Full Text] [Related]
5. How do we interpret the data supporting the use of omalizumab for severe asthma?
Lavietes MH
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):335-6. PubMed ID: 25256024
[No Abstract] [Full Text] [Related]
6. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements.
Hamilton RG
J Allergy Clin Immunol Pract; 2016; 4(2):366-8. PubMed ID: 26968963
[No Abstract] [Full Text] [Related]
8. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
Leuenberger P; Sauty A; Rochat T
Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
11. Basophil activation test: do not lose control.
Maietta G
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):36-7. PubMed ID: 25781191
[No Abstract] [Full Text] [Related]
12. Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations.
Chanez P
Eur Respir J; 2001 Aug; 18(2):249-50. PubMed ID: 11529279
[No Abstract] [Full Text] [Related]
13. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
14. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.
Walters EH; Walters JA; Wood-Baker R
Expert Opin Pharmacother; 2007 Apr; 8(5):585-92. PubMed ID: 17376014
[TBL] [Abstract][Full Text] [Related]
15. The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.
Yalcin AD; Bisgin A
Med Sci Monit; 2012 Aug; 18(8):LE9-10. PubMed ID: 22847211
[No Abstract] [Full Text] [Related]
16. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
Garcia G; Magnan A; Chiron R; Contin-Bordes C; Berger P; Taillé C; Devouassoux G; de Blay F; Couderc LJ; Didier A; O'Callaghan DS; Girodet PO; Bourdeix I; Le Gros V; Humbert M
Chest; 2013 Aug; 144(2):411-419. PubMed ID: 23579324
[TBL] [Abstract][Full Text] [Related]
17. [Programs for continuing medical education: A session; 7. Current topics of asthma treatment--anti-IgE therapy].
Adachi M; Tanaka A
Nihon Naika Gakkai Zasshi; 2012 Mar; 101(3):689-93. PubMed ID: 22620037
[No Abstract] [Full Text] [Related]
18. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab for asthma: indications, off-label uses and future directions.
Ben-Shoshan M
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):183-92. PubMed ID: 20807194
[TBL] [Abstract][Full Text] [Related]
20. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
Aksu K; Kurt E
Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
